A real-life study of the positive response to DAA-based therapies for hepatitis C in Brazil

Vivaldini, Simone Monzani; Ribeiro, Rachel Abraão; Júnior, Gláucio Mosimann; Tonini, Karen Cristine; Pereira, Gérson Fernando Mendes; Araújo, Wildo Navegantes de

doi:10.1016/j.bjid.2021.101573

Cited by 2 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The N-terminal protease and C-terminal helicase domains of HCV NS3 are interdependent, and both enzymatic activities are essential for HCV replication, assembly, and pathogenesis [ 5 ]. Although current treatment therapy, comprising of directly acting antiviral agents (DAAA), is highly effective [ 6 ], still virus in 4-5% of the individuals do not respond to the therapy [ 7 ]. Furthermore, numerous reports have identified the emergence of drug resistance mutations, which can affect the activity of DAAAs [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Molecular docking analysis of fluoroquinolones and other natural and synthetic compounds with the HCV NS3 helicase

Haq¹

2022

Bioinformation

View full text Add to dashboard Cite

It is of an interest to document the molecular docking analysis of fluoroquinolones and other natural and synthetic compounds with the HCV NS3 helicase. Data shows that three fluoroquinolones interacted with the NS3 helicase in the catalytic region, targeting some of the amino acids known to play a crucial role in NS3 helicase activity. Similarly, binding energy shows that the fluoroquinolones were comparable to the thiazolpiperazinyl derivatives, while superior to several of the synthetic and natural derivatives. The results show three fluoroquinolones to be potent helicase inhibitors that can be repurposed as supplemental therapy against HCV especially in cases non-responsive to DAAAs.

show abstract

Section: Introductionmentioning

confidence: 99%